Inhibition of CYP3A mRNA and protein expression, and enzymatic activity, by enrofloxacin in chickens

Journal of Veterinary Pharmacology and Therapeutics

Volumn 33, Issue 6, 2010, Pages 546-550

  Hu, H F ^a   Gao, Z X ^a   Cheng, Y Y ^a  

^a INSTITUTE OF HEALTH AND ENVIRONMENTAL MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; ENROFLOXACIN; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHICKEN; DOSE RESPONSE; DOWN REGULATION; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG RESEARCH; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC TRANSCRIPTION; IMMUNODETECTION; LIVER MICROSOME; MALE; METABOLIC INHIBITION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTI-INFECTIVE AGENTS; BLOTTING, WESTERN; CHICKENS; CYTOCHROME P-450 CYP3A; FLUOROQUINOLONES; GENE EXPRESSION; MALE; MICROSOMES, LIVER; PROTEIN BIOSYNTHESIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

GALLUS GALLUS;

EID: 78349272776     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2010.01175.x     Document Type: Article

References (13)

1. Cerniglia, C.E. & Kotarski, S. (1999) Evaluation of veterinary drug residues in food for their potential to affect human intestinal microflora. Regulatory Toxicology and Pharmacology, 29, 238-261.
2. Lamba, J.K., Lin, Y.S., Schuetz, E.G. & Thummel, K.E. (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Advanced Drug Delivery Reviews, 54, 1271-1294.
3. Martinez, M., McDermott, P. & Walker, R. (2006) Pharmacology of the fluoroquinolones: a perspective for the use in domestic animals. The Veterinary Journal, 172, 10-28.
4. Mayeaux, M.H. & Winston, G.H. (1998) Antibiotic effects on cytochrome P450 content and mixed-function oxygenase (MFO) activities in the American alligator. Alligator mississippiensis. Journal of Veterinary Pharmacology and Therapeutics, 21, 274-281.
5. Oo, C. & Chen, Y.C. (2009) The need for multiple doses of 400-mg ketoconazole as a precipitant inhibitor of a CYP3A substrate in an in vivo drug-drug interaction study. Journal of Clinical Pharmacology, 49, 368-369.
6. Ourlin, J.-C., Baader, M., Fraser, D., Halpert, J.R. & Meyer, U.A. (2000) Cloning and functional expression of a first inducible avian cytochrome P450 of the CYP3A subfamily (CYP3A27). Archives of Biochemistry and Biophysics, 373, 375-384.
7. Roedler, R., Neuhauser, M.M. & Penzak, S.R. (2007) Does metronidazole interact with CYP3A substrates by inhibiting their metabolism through this metabolic pathway? Or should other mechanisms be considered? Annals of Pharmacotherapy, 41, 653-658.
8. Schlosberg, A., Ershov, E., Bellaiche, M., Hanji, V., Weisman, Y. & Soback, S. (1995) The effects of enrofloxacin on hepatic microsomal mixed function oxidase in broiler chicken. Journal of Veterinary Pharmacology and Therapeutics, 18, 311-313.
9. Spiqset, O. & Molden, E. (2008) Cytochrome P-450 3A4- the most important arena for drug interactions in the body. Tidsskr Nor Laeqeforen, 128, 2832-2835.
10. Tamura, G., Satoh, K., Ohtsu, H., Fujimoto, Y., Aizawa, T., Sakai, K., Mue, S. & Takishima, T. (1987) Norfloxacin does not raise theophylline concentrations in plasma. Areruqi, 36, 262-267.
11. Vaccaro, E., Giorgi, M., Longo, V., Mengozzi, G. & Gervasi, P.G. (2003) Inhibition of cytochrome p450 enzymes by enrofloxacin in the sea bass (Dicentrarchus labrax). Aquatic Toxicology, 62, 27-33.
12. Vancutsem, P.M. & Babish, J.G. (1996) In vitro and in vivo study of the effects of enrofloxacin on hepatic cytochrome P450. Potential for drug interactions. Veterinary and Human Toxicology, 38, 254-259.
13. Wijnands, W.J., Vree, T.B. & Van Herwaarden, C.L. (1986) The influence of quinolone derivatives on theophylline clearance. British Journal of Clinical Pharmacology, 22, 677-683.